ProQR Therapeutics Reports Positive Clinical Trial Results Treating LCA10
On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained improvement in their vision, and the treatment was well tolerated with no serious adverse events. As a result, the company decided to suspend admission into this trial and move onto the Phase 2/3 trial.
Rocket Tickers issued an alert about the event at 4:00 am. The next trade took place for $9.00 at 6:03 am. The stock opened for regular market trading at $13.75. The price continued to move higher throughout the day before closing at $17.55 for an event-day gain of 95%.
ProQR Therapeutics’ stock price continued to rise over the next five trading sessions. On September 12, the stock closed at $18.52. That is a 106% increase in the stock price following the announcement!
Visit the Knowledge Center for more information about clinical trials and how to trade them.
Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.
Subscribe here if you would like to start receiving these signals in real-time and start trading!